Original-Research: SYNBIOTIC SE (von NuWays AG): Under review
|
Original-Research: SYNBIOTIC SE - from NuWays AG
Classification of NuWays AG to SYNBIOTIC SE
Portfolio unwound; rating placed Under Review SYNBIOTIC's investment case has changed fundamentally after a wave of insolvencies and liquidations across the portfolio. What began with the Bushdoctor (Austria) insolvency in December 2025 has widened sharply with Hempro International, SOLIDMIND Group and Lean Labs Pharma, alongside the wind-down of the hemp food and feed activities (HANF FARM ceasing operations, Hemp Factory). The common trigger was falling CBD and hemp demand plus regulatory uncertainty, prompting the parent to halt intra-group funding to protect its remaining liquidity. After this clean-up, the operating base is smaller but should also come with a notably reduced fix-cost base (eNuW). A far narrower core. Going forward, resources concentrate on WEECO Pharma (medical cannabis), alongside MH medical hemp and the Croatian isolate manufacturer Ilesol. Mind you, the latter two remain largely CBD / hemp-extract businesses. Hence, WEECO is in practice the single genuinely de-risked pillar, in our view. WEECO the key asset. WEECO Pharma (eNuW: ~ 90% of our FY26e sales estimates), a German importer and wholesale platform connecting international medical-cannabis producers, several of them EU-GMP manufacturers, it sits in the structurally growing, regulation-driven end of the market rather than the CBD side that dragged the other units under. Its pharma-oriented, GMP-track profile offers a more defensible margin and a clearer route to scale once the end-market revitalizes (burdened by over-supply following regulatory changes/uncertainty). Operational base eroded, debt weighs. With most potentially revenue- and cash-generating subsidiaries removed, the group now almost entirely relies on WECCO. While we regard the reset as strategically sensible, i.e. cutting structurally loss-making units lowers recurring cash consumption and sets up a leaner, more focused group, it also raises balance-sheet, liquidity and execution risk, and leaves the equity story dependent on WEECO. Mind you, the German medical cannabis market, especially for value-oriented product groups, is still challenging. Conclusion: Given the uncertainty around the group structure, the crystallising impairments, remaining liquidity and the path to a sustainable model, we place our rating and price target UNDER REVIEW pending audited accounts and clarity on funding. You can download the research here: synbiotic-se-2026-08-24-update-en-6b04f For additional information visit our website: https://www.nuways-ag.com/research Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||
2387160 24.08.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 5,45 | 8,65 | 8,17 | 3,86 | 14,31 | 0,00 | 0,00 | |
| EBITDA1,2 | -0,71 | -4,83 | -7,41 | -7,19 | -2,27 | 0,00 | 0,00 | |
| EBITDA-Margin3 | -13,03 | -55,84 | -90,70 | -186,27 | -15,86 | -11,47 | 0,00 | |
| EBIT1,4 | -0,83 | -11,49 | -25,92 | -11,75 | 10,58 | 0,00 | 0,00 | |
| EBIT-Margin5 | -15,23 | -132,83 | -317,26 | -304,40 | 73,93 | -7,06 | 0,00 | |
| Net Profit (Loss)1 | -0,88 | -13,07 | -26,00 | -11,74 | -10,89 | 0,00 | 0,00 | |
| Net-Margin6 | -16,15 | -151,10 | -318,24 | -304,15 | -76,10 | -8,82 | 0,00 | |
| Cashflow1,7 | -1,26 | -5,14 | -6,99 | -2,92 | -0,50 | 0,00 | 0,00 | |
| Earnings per share8 | -0,56 | -4,15 | -5,97 | -2,25 | -1,66 | -0,37 | -0,19 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Forvis Mazars
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| SynBiotic | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3E5A5 | DE000A3E5A59 | SE | 5,74 Mio € | 11.11.2019 | Beobachten | 9F387R32+8V |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -9,38 | 0,00 | 0,00 | -0,28 | 0,44 | -11,42 | 0,40 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 23.04.2026 | 30.09.2024 | 11.12.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -38,42% | -61,06% | -73,90% | -76,60% | -24,84% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
